Downs Katy, Zacks David N, Caruso Rafael, Karoukis Athanasios J, Branham Kari, Yashar Beverly M, Haimann Mark H, Trzupek Karmen, Meltzer Meira, Blain Delphine, Richards Julia E, Weleber Richard G, Heckenlively John R, Sieving Paul A, Ayyagari Radha
Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA.
Arch Ophthalmol. 2007 Feb;125(2):252-8. doi: 10.1001/archopht.125.2.252.
To describe clinical molecular testing for hereditary retinal degenerations, highlighting results, interpretation, and patient education.
Mutation analysis of 8 retinal genes was performed by dideoxy sequencing. Pretest and posttest genetic counseling was offered to patients. The laboratory report listed results and provided individualized interpretation.
A total of 350 tests were performed. The molecular basis of disease was determined in 133 of 266 diagnostic tests; the disease-causing mutations were not identified in the remaining 133 diagnostic tests. Predictive and carrier tests were requested for 9 and 75 nonsymptomatic patients with known familial mutations, respectively.
Molecular testing can confirm a clinical diagnosis, identify carrier status, and confirm or rule out the presence of a familial mutation in nonsymptomatic at-risk relatives. Because causative mutations cannot be identified in all patients with retinal diseases, it is essential that patients are counseled before testing regarding the benefits and limitations of this emerging diagnostic tool.
The molecular definition of the genetic basis of disease provides a unique adjunct to the clinical care of patients with hereditary retinal degenerations.
描述遗传性视网膜变性的临床分子检测,重点介绍检测结果、解读及患者教育。
采用双脱氧测序法对8个视网膜基因进行突变分析。为患者提供检测前和检测后的遗传咨询。实验室报告列出检测结果并提供个性化解读。
共进行了350次检测。在266次诊断性检测中,确定了133例疾病的分子基础;其余133次诊断性检测未发现致病突变。分别对9例有已知家族性突变的无症状患者和75例进行了预测性检测和携带者检测。
分子检测可确诊临床诊断、确定携带者状态,并确认或排除无症状高危亲属中家族性突变的存在。由于并非所有视网膜疾病患者都能鉴定出致病突变,因此在检测前务必向患者咨询这种新兴诊断工具的益处和局限性。
疾病遗传基础的分子定义为遗传性视网膜变性患者的临床护理提供了独特的辅助手段。